Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Its Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint, announced September 3, 2024 (global statistical test 0.08, P = .70)
T.EvansonN
But It Is Fighting Back
We assume a modest dip in 2026 (patent cliffs begin and lingering COVID sales fall off), then new product growth accelerates
GLP-1 drugs could fill the gap in addiction treatment So far, multiple systemic reviews have been conducted to provide a comprehensive analysis of clinical trials to determine the impact of GLP-1 receptor agonists in reducing substance use disorder in patients
US$ 20.91
US$ 24.10
US$ 29.06
US$ 20.20
US$ 21.08
US$ 23.36
US$ 23.39
US$ 21.18
US$ 23.57
US$ 21.61
US$ 20.96
US$ 29.48
US$ 29.65
US$ 28.48
